The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.
 
Monica F Chen
Stock and Other Ownership Interests - docs; FIGS; Nordisk; Quest Diagnostics
Research Funding - ASCO; NIH
Travel, Accommodations, Expenses - AACR; ASCO
 
Swanand Rakhade
No Relationships to Disclose
 
Alvaro Quintanal-Villalonga
Honoraria - AstraZeneca
Research Funding - Duality Biologics; Foghorn Therapeutics; Jazz Pharmaceuticals
 
Jake Lee
No Relationships to Disclose
 
Britney Forsythe
No Relationships to Disclose
 
Khadeja A. Moses
No Relationships to Disclose
 
Linda Su Hyun Ahn
No Relationships to Disclose
 
Amanda Pupo
No Relationships to Disclose
 
Christina J. Falcon
No Relationships to Disclose
 
Natasha Rekhtman
Honoraria - Merck
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; BerGenBio; Daiichi Sankyo/Astra Zeneca; Merus; Mirati Therapeutics; Pfizer; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Genentech
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Bridge Medicines; D2G Oncology; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Harpoon Therapeutics; Jazz Pharmaceuticals; Kowa; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Joseph Minhow Chan
Consulting or Advisory Role - VantAI
 
Helena Alexandra Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Taiho Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma